Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

ABSTRACT: To clarify the machinery how lenalidomide inhibit proplatelet formation of megakaryocytes, we performed transcriptome analysis of megakaryocytes derived from human hematopoietic stem/progenitor cells in the liquid culture system with or without lenalidomide. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. Untreated megakaryocytes showed the estradiol-responded gene expression signatures, whereas the lenalidomide-treated megakaryocytes did not. Furthermore, we performed a rescue strategy with exogenous estradiol, confirming that lenalidomide-induced inhibition of proplatelet formation should be due to the deficiency of endogenous estradiol action in megakaryocytes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE111994 | GEO | 2018/06/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

Project description:To clarigy the molecular mechanism underlying the IMiD-induced megakaryocytic lineage commitment in human megakaryocyte/erythrocyte progenitors, we performed transcriptome analysis of CD41-CD105+ and CD41+CD105- cells obtained from megakaryocyte/erythrocyte progenitors treated with lenalidomide for 72 hours. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. CD105-CD41+ cells showed the enrichment in the expression of genes related to megakaryocytes and platelet, whereas genes related to erythroid lineage were negatively enriched. CD41+CD105- cells expressed higher levels of transcription factors required for megakaryocyte differentiation including FLI1, RUNX1, and MEIS1. Furthermore, we performed a knockdown strategy with small interfering RNA against MEIS1 mRNA, confirming that lenalidomide-induced megakaryocyte commitment should be due to the up-regulation of MEIS1 in megakaryocyte/erythrocyte progenitors.

2021-11-25 | GSE162212 | GEO

Dual role of EZH2 on megakaryocyte differentiation, ChIP-seq analysis at different stages of megakaryocyte maturation

Project description:EZH2, the enzymatic component of PRC2, has been identified as a key factor in hematopoiesis. EZH2 loss of function mutations have been found in myeloproliferative neoplasms, more particularly in myelofibrosis, but the precise function of EZH2 in megakaryopoiesis is not fully delineated. Here, we show that EZH2 inhibition by small molecules and shRNA induces MK commitment by accelerating lineage marker acquisition without change in proliferation. Later in differentiation, EZH2 inhibition blocks proliferation and endomitosis and decreases proplatelet formation. EZH2 inhibitors similarly reduce polyploidization and proplatelet formation of JAK2V617F MK. In transcriptome profiling, the defect in proplatelet formation was associated with an aberrant actin cytoskeleton regulation pathway, whereas polyploidization was associated with an inhibition of expression for a set of genes involved in DNA replication and repair, and an upregulation of CDK inhibitors, more particularly CDKN1A and CDKN2D. The knockdown of CDKN1A and/or CDKN2D could partially rescue the percentage of polyploid MKs. However only CDKN1A was regulated by H3K27me3 suggesting that EZH2 controls MK polyploidization through a direct regulation of CDKN1A and indirectly of CDKN2D.

2021-03-31 | E-MTAB-8611 | biostudies-arrayexpress

Mass spectrometry-based characterisation of human megakaryocyte CRLF3 interactome

Project description:Cytokine-receptor like factor 3 (CRLF3) is a protein with an as yet unknown function. CRLF3 has been shown to interact with the members of the Hippo pathway in HEK cells but the function of this interaction was not elucidated. Crlf3 null mice are viable and health but present with an isolated reduced platelet count from birth, confirming CRLF3 has a role in platelet production. We performed affinity purification followed by liquid chromatography coupled to tandem mass spectrometry to identify CRLF3’s binding partners in human megakaryocytes.

2022-02-04 | PXD017026 | Pride

Increased lipid transport and de novo synthesis lead to dynamic lipidome remodeling and regulation of lipid-dependent kinases during megakaryopoiesis and proplatelet formation

Project description:During megakaryopoiesis and consecutive platelet production, megakaryocytes undergo robust cellular morphological changes which are associated with the reprogramming of signaling pathways. Moreover, it can be assumed that lipid membrane composition and signaling are strongly modified. However, the knowledge of lipid alteration during megakaryopoiesis and which pathways are involved is still lacking. Here, we use a lipid-centric multiomics approach to create a quantitative map of the megakaryocyte lipidome during maturation and proplatelet formation. Our data reveal that megakaryocyte differentiation is driven by an increased fatty acyl import and de novo lipid synthesis, resulting in the modulation towards an anionic membrane phenotype. This phenotype and the upregulation of diacylglycerols highly correlate with the activation of lipid-dependent kinases such as PKC and BTK. Using inhibitors of fatty acid import and phospholipid synthesis proved to block membrane remodeling and kinase activation and directly reduced proplatelet formation. Altogether, this study provides a framework for understanding how membrane lipid remodeling during megakaryocyte differentiation impacts kinase signaling and proplatelet formation while providing a knowledge base to exploit megakaryopoiesis.

2023-08-22 | PXD037622 | Pride

Dual role of EZH2 on megakaryocyte differentiation, analysis on mature megakaryocytes at day 13 of culture

2021-11-02 | E-MTAB-8609 | biostudies-arrayexpress

Dual role of EZH2 on megakaryocyte differentiation, analysis at different stages of maturation at day 9 of culture

2021-11-02 | E-MTAB-8610 | biostudies-arrayexpress

Effect of Lenalidomide on human macrophages.

Project description:Lenalidomide, an IMiD® immunomodulatory agent used for the treatment of multiple myeloma (MM),is believed to target the stromal support, but its precise mechanism on the phenotype or the effector functions of macrophages is still unclear. To investigate the effect of lenalidomide on macrophages, M-CSF generated macrophages were treated with Lenalidomide and analyzed by RNA-seq.

2021-01-23 | GSE165332 | GEO

Transcriptome analysis of productive and unproductive pathways of in vitro megakaryocytopoiesis and their control by he AHR antagonist SR1

Project description:Human CD34+ progenitors can be in vitro differentiated into proplatelet-producing megakaryocytes (MKs) within 17 days. During this course, 4 cell populations emerge, phenotypically defined as CD34+CD41+ at day 7 (D7) and CD34+CD41+CD9- at D10 and D14 —qualified as “productive” because they can differentiate into proplatelet-forming cells during the D14-D17 period— and CD34-CD41+ or CD34+CD41+CD9+ at day 10 —qualified as “unproductive”, because unable to form proplatelets later. The productive pathway is boosted by the addition of SR1 at D0 and D7. To clarify the features of the productive and unproductive pathways, as well as the effect of SR1, the transcriptomes of the cell populations present at D0, 7, 10 and 14, generated in the presence of the absence of SR1 were determined by RNA-Seq.

2021-06-30 | GSE167866 | GEO

thrombopoietin-induced megakaryocyte differentiation with and without nicotinamide

Project description:Culture of hematopoietic stem and progenitor cells in the presence of thrombopoietin induces megakaryocytic differentiation. Addition of nicotinamide to thrombopoietin-stimulated cultures results in significant increases in megkaryocytic differentiation including greater polyploidization and enhanced proplatelet formation. This study focuses on understanding the differences in the temporal gene expression pattern during differentiation with and without nicotinamide. Nicotinamide was added on day 5. Keywords: treatment response

2006-08-25 | GSE4974 | GEO

Critical shifts in lipid metabolism promote megakaryocyte differentiation and proplatelet formation (Shotgun lipidomics assays without inhibition)

Project description:During megakaryopoiesis, megakaryocytes (MK) undergo cellular morphological changes with strong modification of membrane composition and lipid signaling. Here we adopt a lipid-centric multi-omics approach to create a quantitative map of the MK lipidome during maturation and proplatelet formation. Data reveal that MK differentiation is driven by an increased fatty acyl import and de novo lipid synthesis, resulting in an anionic membrane phenotype. Pharmacological perturbation of fatty acid import and phospholipid synthesis blocked membrane remodeling and directly reduced MK polyploidization and proplatelet formation resulting in thrombocytopenia. The anionic lipid shift during megakaryopoiesis was paralleled by lipid-dependent relocalization of the scaffold protein CKIP-1 and recruitment of the kinase CK2α to the plasma membrane, which seems to be essential for sufficient platelet biogenesis. Overall, this study provides a framework to understand how the MK lipidome is altered during maturation and the impact of MK membrane lipid remodeling on MK kinase signaling involved in thrombopoiesis. Shotgun lipidomics assays without inhibition are reported in the current study MTBLS6082Shotgun lipidomics assays after inhibition with FSG67 and Triacsin C are reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS6083' rel='noopener noreferrer' target='_blank'>MTBLS6083</a>Targeted lipidomics assay without inhibition are reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS6084' rel='noopener noreferrer' target='_blank'>MTBLS6084</a>

2023-07-26 | MTBLS6082 | MetaboLights

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data